Patents for A61P 35 - Antineoplastic agents (221,099)
04/2002
04/11/2002WO2002029060A2 Hematopoietin receptors hpr1 and hpr2
04/11/2002WO2002029058A2 Human proteins, polynucleotides encoding them and methods of using the same
04/11/2002WO2002029057A2 32144, a human fatty acid amide hydrolase and uses thereof
04/11/2002WO2002029055A2 Carbohydrate-associated proteins
04/11/2002WO2002029053A1 Novel g protein-coupled receptor protein and dna thereof
04/11/2002WO2002029038A2 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
04/11/2002WO2002029036A2 Lipid metabolism enzymes
04/11/2002WO2002029035A2 Method to alter sugar moieties
04/11/2002WO2002029031A2 Isoprenoid-dependent ras anchorage (idra) proteins
04/11/2002WO2002028906A2 Regulation of human sphingosine kinase-like protein
04/11/2002WO2002028905A2 Human anti-cd40 antibodies
04/11/2002WO2002028904A2 Human anti-cd40 antibodies
04/11/2002WO2002028902A2 Nectin polypeptides, polynucleotides, methods of making and use thereof
04/11/2002WO2002028895A2 Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator
04/11/2002WO2002028894A1 Gene relating to drug tolerance and utilization thereof
04/11/2002WO2002028887A2 Use of lipopeptides or lipoproteins for treating lung infections and lung tumours
04/11/2002WO2002028874A2 Tumor proliferation inhibitors
04/11/2002WO2002028871A1 Platinum complexes as antitumor agents
04/11/2002WO2002028869A1 Gamma-glutamyl transpeptidase inhibitors
04/11/2002WO2002028867A2 Ethers of 7-desmethylrapamycin for use in immunosuppression
04/11/2002WO2002028866A2 Hydroxyesters of 7-desmethylrapamycin
04/11/2002WO2002028865A2 Condensed pyridoindole derivatives
04/11/2002WO2002028861A2 Methods and compounds for treating proliferative diseases
04/11/2002WO2002028860A2 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
04/11/2002WO2002028859A2 Condensed pyridoindole derivatives
04/11/2002WO2002028858A2 Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
04/11/2002WO2002028856A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases
04/11/2002WO2002028855A2 Amorphous form of cell cycle inhibitor
04/11/2002WO2002028832A2 Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
04/11/2002WO2002028831A1 Inhibitors of prenyl-protein transferase
04/11/2002WO2002028828A1 Substituted (e)-styryl benzylsulfones for treating proliferative disorders
04/11/2002WO2002028810A2 Retinoids for the treatment of emphysema
04/11/2002WO2002028481A2 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
04/11/2002WO2002028480A2 Methods of therapy for b-cell malignancies
04/11/2002WO2002028440A1 Methods and compositions for modulating t cell activation and uses thereof
04/11/2002WO2002028432A2 Stem cell-based methods for preventing and treating tumor
04/11/2002WO2002028424A2 Kyberdrug as autovaccines with immune-regulating effects
04/11/2002WO2002028420A2 Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules
04/11/2002WO2002028418A1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists
04/11/2002WO2002028414A1 Compositions and methods for wt1 specific immunotherapy
04/11/2002WO2002028409A2 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
04/11/2002WO2002028408A2 Compositions and methods for the transport of biologically active agents across cellular barriers
04/11/2002WO2002028399A1 Apoptosis inducers, caspase cascade activators and anticancer agents
04/11/2002WO2002028396A1 Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid
04/11/2002WO2002028395A1 Phosphoric acid salt of an integrin receptor antagonist
04/11/2002WO2002028389A1 Antitumor therapy comprising distamycin derivatives
04/11/2002WO2002028381A2 Methods of inducing cancer cell death and tumor regression
04/11/2002WO2002028380A2 Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
04/11/2002WO2002028377A1 Ihnalation particles incorporating a combination of two or more active ingredients
04/11/2002WO2002028349A2 Method of treating cancer using dithiocarbamate derivatives
04/11/2002WO2002028347A2 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
04/11/2002WO2002028345A2 Aldehyde-releasing compounds
04/11/2002WO2002028165A2 Compositions and methods of using capsid protein from flaviviruses and pestiviruses
04/11/2002WO2002016401A3 Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
04/11/2002WO2002007514A3 Glycosylated vegf-b and method for increasing the amount of soluble vegf-b
04/11/2002WO2002006300A3 Mutated pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiogenesis
04/11/2002WO2001094279A3 Purification of xanthophylls from marigold extracts that contain high levels of chlorophylls
04/11/2002WO2001092581A8 Compositions and methods for the therapy and diagnosis of ovarian cancer
04/11/2002WO2001092308A3 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
04/11/2002WO2001090070A3 Caspase inhibitors and uses thereof
04/11/2002WO2001090069B1 Novel calcium receptor active molecules and method for preparing same
04/11/2002WO2001085671A3 Anthranyl amides and their use as medicaments
04/11/2002WO2001083450A3 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
04/11/2002WO2001082963A3 Method of identifying and producing antigen peptides and use thereof as vaccines
04/11/2002WO2001076572A3 Use of compatible solutes as substances having free radical scavenging properties
04/11/2002WO2001074856A3 Wnt-7b-like polypeptides and nucleic acids encoding same
04/11/2002WO2001072780A3 Polynucleotides for diagnosing mammary gland cancer
04/11/2002WO2001070174A3 Vegf-modulated genes and methods employing them
04/11/2002WO2001058937A3 Interferon-alpha induced genes
04/11/2002WO2001058477A3 Immunization of an individual against carcinoma and the preliminary stages thereof
04/11/2002WO2001057209A3 Novel family of proteins, called atip, nucleic sequences coding for same and uses thereof
04/11/2002WO2001053835A3 Methods for detecting cancer of the central nervous system
04/11/2002WO2001036616A3 Acid nucleic construct bearing a system regulating the expression of a gene
04/11/2002WO2001036374A3 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments
04/11/2002WO2001032680A3 18-nor-steroids as selectively active estrogens
04/11/2002WO2001022920A8 Colon and colon cancer associated polynucleotides and polypeptides
04/11/2002WO2000052210A3 Methods for targeting rna molecules
04/11/2002WO2000045805A9 Methods of inhibiting the hgf-met-upa-plasmin network with geldanamycin derivates
04/11/2002US20020042535 Therapeutic compounds and methods of use
04/11/2002US20020042517 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
04/11/2002US20020042513 Therapeutic compounds
04/11/2002US20020042443 Estrogen agonist / antagonist metabolites
04/11/2002US20020042441 N-substituted indoles useful in the treatment of diabetes
04/11/2002US20020042435 Cyclic AMP-specific phosphodiesterase inhibitors
04/11/2002US20020042427 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
04/11/2002US20020042421 Antiinflammatory agents
04/11/2002US20020042412 Fused azepinone cyclin dependent kinase inhibitors
04/11/2002US20020042409 Thiophene derivatives useful as anticancer agents
04/11/2002US20020042392 Anticancer agents
04/11/2002US20020042391 Anticancer agents; viricides
04/11/2002US20020042389 IGF-1 receptor interacting proteins
04/11/2002US20020042385 Cloning of a novel 7TM receptor AXOR-2
04/11/2002US20020042368 Integrin antagonists
04/11/2002US20020042114 Novel human protein kinases
04/11/2002US20020042101 Nucleotide sequences which code enzymatic polypeptide for use in the treatment of cancer, restenosis and diabetic neuropathy
04/11/2002US20020042091 Methods and compositions for screening modulators of lipid kinases
04/11/2002US20020041905 Solvent extraction of plant extracts; activation; antituor agents
04/11/2002US20020041898 Novel targeted delivery systems for bioactive agents
04/11/2002US20020041897 In biocompatible polymer
04/11/2002US20020041888 Suspension containing microspheres; apoptosis inducing compound